{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001105","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.672395+00:00","generated_at":"2026-05-26T02:20:44.855124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025","bullets":["Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).","Cash and marketable securities $127M, down from $152M; cash runway into 2027.","Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.","Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.","CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001105","json":"https://secwatch.observer/filing/0001171843-25-001105.json","markdown":"https://secwatch.observer/filing/0001171843-25-001105.md","text":"https://secwatch.observer/filing/0001171843-25-001105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/0001171843-25-001105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/f8k_022625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:20:44.855124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}